ALK and large cell neuroendocrine carcinoma: This stepwise development of ALK-dependent resistance under alectinib may be an argument for earlier use of lorlatinib in ALK+ LCNEC, besides the higher potency of the drug, as reflected in the limited clinical benefit from crizotinib, ceritinib, and brigatinib in our patient.